Immune to Cancer: The CRI Blog
-
PORTER Immunotherapy Clinical Trial for Prostate Cancer Unveiled at SITC2019
Details of a promising new CRI co-funded clinical trial for metastatic prostate cancer unveiled at the 2019…
-
CRI-Funded Trial Reveals Promising Potential of Immunotherapy Combination in Metastatic Pancreatic Cancer
Interim data from a novel immunotherapy-chemotherapy combination that targets the CD40 and PD-1 pathways show promising anti-tumor…
-
The Power of Transformational Gifts
Atlantic Philanthropies, a large charitable foundation, recently released a report summarizing the group's investments in cancer and…
-
Advocating for Innovative Clinical Trial Design
Laura Pearce, CRI consultant and head of clinical alliances, participates in a clinical trials panel on platform…
-
AACR18 Update: Lloyd J. Old Award, Overcoming Immunotherapy Resistance, and the Importance of Dendritic Cells
Day 4 at AACR18 was a special day for CRI’s Dr. Antoni Ribas, and highlighted his and…
-
AACR18 Day 3 Update: Lung Cancer in the Spotlight, Immune Memory, and New Immunotherapy Biomarkers
Day 3 of AACR18 highlighted potentially “practice-changing” immunotherapy breakthroughs in lung cancer, and insights into the factors…
-
AACR18 Day 2 Update: What’s Next for Cancer Immunotherapy?
CRI scientists kicked off the opening plenary session at AACR18 and discussed several promising avenues of immunotherapy…
-
Immunotherapy is Here to Stay: Looking Back at this Year’s Breakthroughs
Important immunotherapy breakthroughs benefited patients immensely in 2017 and paved the way for even more advances in…
-
Immunotherapy in the Fast Lane: CRI’s Clinical Accelerator Takes Off
The Clinical Accelerator is able to identify new potentially life-saving treatments and then foster collaboration among the…